LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5
Abstract A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated. lncRNAs involve in drug resistance in some cancers, however, the exact functions of lncRNA colon c...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-05-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-11644-4 |
| _version_ | 1828221846686793728 |
|---|---|
| author | Chongsheng Xia Yurui Sun Yang Li Junli Ma Jing Shi |
| author_facet | Chongsheng Xia Yurui Sun Yang Li Junli Ma Jing Shi |
| author_sort | Chongsheng Xia |
| collection | DOAJ |
| description | Abstract A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated. lncRNAs involve in drug resistance in some cancers, however, the exact functions of lncRNA colon cancer-associated transcript 1 (CCAT1) in oxaliplatin resistance in HCC are still unknown. Our study indicated that CCAT1 promoted HCC proliferation and reduced the apoptosis induced by oxaliplatin. Knockout of CCAT1 could increased chemosensitivity in vitro and in vivo. Further study found that QKI-5 was an important mediator and blocking of QKI-5/p38 MAPK signaling pathway could enhance oxaliplatin sensitivity. In conclusions, CCAT1 promoted proliferation and oxaliplatin resistance via QKI-5/p38 MAPK signaling pathway in HCC. Targeting CCAT1 in combination with chemotherapeutics may be a promising alternative to reverse drug resistance in HCC treatment. |
| first_indexed | 2024-04-12T16:47:04Z |
| format | Article |
| id | doaj.art-6028f4db023e426f8cc8cde9a476f20a |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-12T16:47:04Z |
| publishDate | 2022-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-6028f4db023e426f8cc8cde9a476f20a2022-12-22T03:24:33ZengNature PortfolioScientific Reports2045-23222022-05-011211910.1038/s41598-022-11644-4LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5Chongsheng Xia0Yurui Sun1Yang Li2Junli Ma3Jing Shi4Affiliated Hospital of Jining Medical UniversityAffiliated Hospital of Jining Medical UniversityAffiliated Hospital of Jining Medical UniversityAffiliated Hospital of Jining Medical UniversityAffiliated Hospital of Jining Medical UniversityAbstract A major reason for treatment failure of cancer is acquisition of drug resistance. The specific mechanisms underlying hepatocellular carcinoma (HCC) chemoresistance need to be fully elucidated. lncRNAs involve in drug resistance in some cancers, however, the exact functions of lncRNA colon cancer-associated transcript 1 (CCAT1) in oxaliplatin resistance in HCC are still unknown. Our study indicated that CCAT1 promoted HCC proliferation and reduced the apoptosis induced by oxaliplatin. Knockout of CCAT1 could increased chemosensitivity in vitro and in vivo. Further study found that QKI-5 was an important mediator and blocking of QKI-5/p38 MAPK signaling pathway could enhance oxaliplatin sensitivity. In conclusions, CCAT1 promoted proliferation and oxaliplatin resistance via QKI-5/p38 MAPK signaling pathway in HCC. Targeting CCAT1 in combination with chemotherapeutics may be a promising alternative to reverse drug resistance in HCC treatment.https://doi.org/10.1038/s41598-022-11644-4 |
| spellingShingle | Chongsheng Xia Yurui Sun Yang Li Junli Ma Jing Shi LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 Scientific Reports |
| title | LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 |
| title_full | LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 |
| title_fullStr | LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 |
| title_full_unstemmed | LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 |
| title_short | LncRNA CCAT1 enhances chemoresistance in hepatocellular carcinoma by targeting QKI-5 |
| title_sort | lncrna ccat1 enhances chemoresistance in hepatocellular carcinoma by targeting qki 5 |
| url | https://doi.org/10.1038/s41598-022-11644-4 |
| work_keys_str_mv | AT chongshengxia lncrnaccat1enhanceschemoresistanceinhepatocellularcarcinomabytargetingqki5 AT yuruisun lncrnaccat1enhanceschemoresistanceinhepatocellularcarcinomabytargetingqki5 AT yangli lncrnaccat1enhanceschemoresistanceinhepatocellularcarcinomabytargetingqki5 AT junlima lncrnaccat1enhanceschemoresistanceinhepatocellularcarcinomabytargetingqki5 AT jingshi lncrnaccat1enhanceschemoresistanceinhepatocellularcarcinomabytargetingqki5 |